/Companies

Biotech Startups

11,050 companies tagged Biotech, with their investors and founders.

MedAvail Holdings

0 investors

MedGene Therapeutics

0 investors

Medgenics

0 investors

Medical 21

Medical 21 develops the MAVERICS Graft, a synthetic regenerative vascular graft that lets surgeons perform complete cardiac bypass procedures without harvesting the patient's own blood vessels. The graft uses a nitinol scaffold and stimulates angiogenesis so the body forms an arterial-like vessel from the patient's own cells, targeting coronary bypass surgery.

0 investors

Medical Engineering Partners

0 investors

Medical Mirror Systems

0 investors

Medical Nutrition Innovation

0 investors

Medici Therapeutics

0 investors

Medicovestor

0 investors

Medicus Pharma

Medicus Pharma is a biotech company that identifies, acquires, and advances clinical-stage therapeutic assets through development and commercialization. The company focuses on addressing unmet medical needs across diverse therapeutic areas.

0 investors

Medite Cancer Diagnostics

0 investors

Meditope Biosciences

Meditope is a biotechnology company developing SnAP technology for antibody design, with a focus on creating more efficacious, safer, and cost-efficient antibody-based therapeutic products.

0 investors

MEDPhlow

0 investors

Medsyn Biopharma

0 investors

MedVector

0 investors

MedWand Solutions

0 investors

Meissa Vaccines

0 investors

Mekiri Bio

0 investors

Mel-Mont Medical

Mél Mont Medical develops a self-collection vaginal sampling device called Mía for cervical cancer screening that detects high-risk HPV DNA and active oncogenic E6/E7 mRNA overexpression without a speculum. The test is designed for women over 25 and provides actionable results to guide follow-up treatment decisions and prevent unnecessary procedures.

0 investors

Melinta Therapeutics INC /New

0 investors

MelioLabs

0 investors

Melt Pharmaceuticals

0 investors

Memgen

Memgen develops viral, cell-based, and vaccine adjuvant immunotherapies built on its proprietary CD40 ligand technology for treating cancer. Its lead candidate, MEM-288, combines the CD40 ligand with interferon beta and is in phase 1 clinical trials for advanced non-small cell lung cancer.

0 investors

Memory MD

0 investors

Other sectors & tags